Novartis AG has heralded another strong quarter of sales growth for Entresto but is setting up its defences to keep the threat of generic competition at bay, while planning for further growth in the lucrative China market.
Fourth-quarter sales of Entresto (sacubitril/valsartan) shot up by 24% to $924m, which the company said was due to sustained strong...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
